ライフサイエンスコーパス: cholesterol-lowering drug

1 hway and is inhibited by statins, a class of cholesterol-lowering drugs.

2 effects of rechallenge with statins or other cholesterol-lowering drugs.

3 and cardiac events compared with usual-care cholesterol-lowering drugs.

4 rial interventions including another type of cholesterol-lowering drug and (2) inclusion of data on d

5 For rosuvastatin, a cholesterol-lowering drug and OATP1A/1B substrate, the l

6 disease; and 44% and 50% taking statin-class cholesterol-lowering drugs and aspirin, respectively.

7 nd the development of the newly approved LDL-cholesterol-lowering drugs and critically review their e

8 coronary events in comparison to usual-care cholesterol-lowering drugs and whether perfusion changes

9 iation between statin use (vs. no use of any cholesterol-lowering drug) and the risk of having abnorm

10 cholesterol diet, with or without ezetimibe (cholesterol-lowering drug), and high-fat/high-cholestero

11 between high circulating cholesterol levels, cholesterol-lowering drugs, and breast cancer are confli

12 etitively, reduce LDL levels more than other cholesterol-lowering drugs, and lower triglyceride level

13 of renal patients of interventions (such as cholesterol-lowering drugs, antihypertensives, aspirin,

14 t studies have indicated statins, a class of cholesterol-lowering drugs, as a potential therapy for A

15 ssociated with increased AD risk, and use of cholesterol-lowering drugs associated with decreased ris

16 e KRAS(G12D)-induced LCH-like mouse with the cholesterol-lowering drug atorvastatin ameliorated the p

17 lytic process involved in the synthesis of a cholesterol-lowering drug, atorvastatin (Lipitor), and w

18 (HMG-CoA) reductase inhibitors are powerful cholesterol-lowering drugs, but their broad use in trans

19 An important example of such drugs are the cholesterol-lowering drugs called 'statins', including Z

20 eral decades are needed to determine whether cholesterol-lowering drugs cause cancer in humans.

21 tin, a Food and Drug Administration-approved cholesterol-lowering drug, could protect against nigrost

22 lutaryl-CoA reductase inhibitors, a class of cholesterol-lowering drugs, could interrupt Ang II signa

23 n of Atorvastatin (AT) versus the non-statin cholesterol-lowering drug, Ezetimibe (EZT) on severity o

24 holesterol homeostasis and its response to a cholesterol-lowering drug, ezetimibe.

25 The medications were pravastatin, a cholesterol-lowering drug for the prevention of cardiova

26 Current use of cholesterol-lowering drugs for five or more years was no

27 Statins were designed as cholesterol-lowering drugs for the prevention of coronar

28 metabolites in fungi, such as lovastatin, a cholesterol-lowering drug from Aspergillus terreus.

29 Lovastatin, a cholesterol-lowering drug, has antiproliferative propert

30 itors, which are the most commonly used oral cholesterol-lowering drugs, have immunomodulatory proper

31 d not forget that niacin is an effective LDL-cholesterol-lowering drug in patients with high LDL leve

32 antihyperglycaemic drugs and non-statin LDL-cholesterol-lowering drugs in patients with type 2 diabe

33 Statins, cholesterol-lowering drugs, inhibit these deleterious pr

34 to oral hypoglycemic, antihypertensive, and cholesterol-lowering drugs into its Medicare Advantage q

35 of nonsteroidal anti-inflammatory drugs and cholesterol-lowering drugs is consistent with a macropha

36 tal structures of hCE1 in complexes with the cholesterol-lowering drug mevastatin, the breast cancer

37 e relative risk for current users of general cholesterol-lowering drugs, mostly statins in this cohor

38 later in life and maternal intervention with cholesterol-lowering drugs or antioxidants reduce postna

39 Here, I propose that rather than being cholesterol-lowering drugs per se, statins act as vitami

40 ned the association between long-term use of cholesterol-lowering drugs, predominantly statins, and t

41 tivating the apoAI gene or administering the cholesterol-lowering drug probucol.

42 late caveolin/caveolae expression, including cholesterol-lowering drugs, reversed the increased CCE a

43 The cholesterol-lowering drug simvastatin has been shown to

44 The cholesterol-lowering drug simvastatin promotes bone form

45 n of hPXR both alone and in complex with the cholesterol-lowering drug SR12813 at resolutions of 2.5

46 ns with the 231 patients who did not use any cholesterol-lowering drugs, statin use was associated wi

47 The widely used cholesterol-lowering drugs, statins, were reported to re

48 the common chiral side chain of statin-type cholesterol-lowering drugs such as Lipitor (atorvastatin

49 s that could cause adverse drug reactions to cholesterol-lowering drugs such as statins.

50 Similarly, pravastatin, another cholesterol-lowering drug, suppressed microglial inflamm

51 Statins are cholesterol-lowering drugs, targeting HMG-CoA reductase,

52 treatment of macrophages with lovastatin, a cholesterol-lowering drug that blocks farnesylation and

53 when the mice were treated with Ezetimibe, a cholesterol-lowering drug that blocks intestinal dietary

54 Statins are widely prescribed cholesterol-lowering drugs that are a first-line treatme

55 Statins are cholesterol-lowering drugs that have been proven in rand

56 e A (HMG-CoA) reductase enzyme (statins) are cholesterol-lowering drugs that have shown promise as th

57 Statins are cholesterol-lowering drugs that inhibit 3-hydroxy-3-meth

58 Statins are effective cholesterol-lowering drugs that reduce the risk of cardi

59 Statins are widely used cholesterol-lowering drugs that selectively inhibit the

60 a decade after the approval of the last LDL-cholesterol-lowering drug, the cholesterol absorption in

61 cal pathway has given rise to a new class of cholesterol-lowering drugs, the proprotein convertase su

62 ls using non-physiological high fat diets or cholesterol-lowering drugs to modify plasma cholesterol,

63 s statins, account for the great majority of cholesterol-lowering drug use.

64 acy of statins, the most prescribed class of cholesterol-lowering drugs used for the prevention and t

65 In the analysis of general cholesterol-lowering drugs, we ascertained 3420 cases of

66 Simvastatin is a cholesterol-lowering drug whose pleiotropic effects may

67 ed in part on the assumption that overuse of cholesterol-lowering drugs will otherwise become a probl